Additional file 4: of Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis
Eduardo Castañón
Christian Rolfo
David Viñal
Inés López
Juan Fusco
Marta Santisteban
Patricia Martin
Leire Zubiri
José Echeveste
Ignacio Gil-Bazo
10.6084/m9.figshare.c.3623249_D3.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_of_Impact_of_epidermal_growth_factor_receptor_EGFR_activating_mutations_and_their_targeted_treatment_in_the_prognosis_of_stage_IV_non-small_cell_lung_cancer_NSCLC_patients_harboring_liver_metastasis/4400564
Table S4. Univariate Regression Model for predicting OS (overall survival) in our clinical series.
2015-08-07 05:00:00
Liver metastasis
Non-small cell lung cancer (NSCLC)
Epidermal growth factor receptor (EGFR)
EGFR tyrosin-kinase inhibitors
Prognosis